Who
Mark C. Schneyer
EVP, Chief Financial Officer
Company insider
Files Form 4 as: EVP, Chief Financial Officer, ACADIA Pharmaceuticals.
In numbers
- Trades disclosed
- 121
- Buys
- 0
- Sells
- 29
- Bought
- $0
- Sold
- $4.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Feb 2022
- Last trade
- 6 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Aug 2026filed 7 Aug 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $255K14,292 at $17.84 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —14,292 at $0.00 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $145K5,000 at $29.00 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $273K9,292 at $29.34 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —14,292 at $0.00 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $255K14,292 at $17.84 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $145K5,000 at $29.00 | filing |
| 6 Aug 2026filed 7 Aug 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $273K9,292 at $29.34 | filing |
| 5 Aug 2026filed 7 Aug 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $104K5,849 at $17.84 | filing |
| 5 Aug 2026filed 7 Aug 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $170K5,849 at $29.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,849 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —5,849 at $0.00 | filing |
| 5 Aug 2026filed 7 Aug 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $104K5,849 at $17.84 | filing |
| 5 Aug 2026filed 7 Aug 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $170K5,849 at $29.00 | filing |
| 4 May 2026filed 5 May 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $76K3,506 at $21.79 | filing |
| 4 May 2026filed 5 May 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $76K3,506 at $21.79 | filing |
| 1 May 2026filed 5 May 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —6,815 | filing |
| 1 May 2026filed 5 May 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,815 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | ACAD ACADIA Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —6,815 at $0.00 | filing |
| 1 May 2026filed 5 May 2026 | ACAD ACADIA PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | —6,815 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)ACAD · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)ACAD · dailypolitical.com · 15 Oct 2026ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Neutral" at UBS GroupACAD · themarketsdaily.com · 13 Oct 2026
0 headlines in the last 90 days name Mark C. Schneyer; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.